India·Source-based summary
Why India rejected a patent application forshorter drug-resistant TB treatment | Explained
The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
This is a source-based summary, not original reporting by Ebenezer journalists. Source: The Hindu. Ebenezer published 29 Oct 2026, 07:52 am. Editorial policy.
Read the original report on The Hindu →
India — The Hindu

